Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Random mutagenesis of the B'A' core domain of yeast DNA topoisomerase II and large-scale screens of mutants resistant to the anticancer drug etoposide.

Biochemical and biophysical research communications - 11 Feb 2005

Jiang Xiaofeng

Abstract excerpt

Mutagenic PCR method was applied to introduce point mutations to the B'A' core domain of yeast DNA topoisomerase II. Screens for mutants resistant to the anticancer drug etoposide were carried out in a yeast ts system in the presence of high concentrations of the drug or in a drug-hypersensitive genetic background. 129 mutants were obtained from a total of 47,000 transformants. Nucleotide sequencing of 40...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amino Acid Substitution
Share to Amsacrine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents

Share to DNA Topoisomerases, Type II

Share to Drug Resistance, Neoplasm

Share to Etoposide

Share to Mutagenesis

Share to Topoisomerase II Inhibitors

Source

Identifiers

PMID: 15629155
DOI: 10.1016/j.bbrc.2004.12.049

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Random mutagenesis of the B'A' core domain of yeast DNA topoisomerase II and large-scale screens of mutants resistant to the anticancer drug etoposide.PMID 15629155Read ↗

Yeast topoisomerase II mutants resistant to anti-topoisomerase agents: identification and characterization of new yeast topoisomerase II mutants selected for resistance to etoposide.Semantic proximity Read ↗

Using yeast to study resistance to topoisomerase II-targeting drugs.Semantic proximity Read ↗

Binding of etoposide to topoisomerase II in the absence of DNA: decreased affinity as a mechanism of drug resistance.Semantic proximity Read ↗

Mutation E522K in human DNA topoisomerase IIbeta confers resistance to methyl N-(4'-(9-acridinylamino)-phenyl)carbamate hydrochloride and methyl N-(4'-(9-acridinylamino)-3-methoxy-phenyl) methane sulfonamide but hypersensitivity to etoposide.Semantic proximity Read ↗

Complementation of temperature-sensitive topoisomerase II mutations in Saccharomyces cerevisiae by a human TOP2 beta construct allows the study of topoisomerase II beta inhibitors in yeast.Semantic proximity Read ↗

Analysis of yeast DNA topoisomerase II mutants resistant to the antitumor drug amsacrine.Semantic proximity Read ↗

Yeast as a model organism for studying the actions of DNA topoisomerase-targeted drugs.Semantic proximity Read ↗

Studying DNA topoisomerase I-targeted drugs in the yeast. Saccharomyces cerevisiae.Semantic proximity Read ↗

Yeast as a genetic model system for studying topoisomerase inhibitors.Semantic proximity Read ↗

Mutations in the proteolipid subunits of the vacuolar H+-ATPase provide resistance to indolotryptoline natural products.Semantic proximity Read ↗

Mutations in the gyrB domain of eukaryotic topoisomerase II can lead to partially dominant resistance to etoposide and amsacrine.Semantic proximity Read ↗

Amsacrine-induced mutations in AS52 cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.